UNSPSC 51393203: Meluadrine

This classification denotes a bronchodilator and beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FYC8314117. European Medicines Agency schedules Meluadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08730MIG. Meluadrine generally arises in the molecular formula C12H18CLNO2.

The term MELUADRINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) Most nations schedule meluadrine under HS 29225000 and SITC 51467. As of Q4 2014, MELUADRINE remains the US FDA Preferred Term for this commodity. Meluadrine bears US NLM identifiers UMLS ID C1881776 and NCI Concept Code C66083. SMILES: CC(C)(C)NCC(C1=C(C=C(C=C1)O)CL)O.

UNSPSC 51393203 Meluadrine, a Commodity code, describes pharmaceutical products and medical supplies procured by state and local health and human services agencies, including emergency response medications, drug deactivation systems, and pharmacy benefit management solutions. State and local governments buy naloxone and opioid-response medications, safe drug deactivation and disposal systems, and ancillary pharmaceutical services under this code. The issuing bodies include county health departments, state health and human services commissions, and municipal emergency management agencies. Recent solicitations span both routine consumables procurement and strategic pharmacy benefit program redesigns, reflecting the code's breadth across emergency response stock and pharmacy operations.

Activity appears concentrated in Florida and Texas, with Seminole County and the Texas Health and Human Services Commission posting distinct procurement approaches. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems through competitive bidding, with a response deadline of July 26, 2023, and quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, reflecting early-stage market research into pharmacy benefit program restructuring. The Seminole County solicitation includes drug-free workplace certification, E-Verify compliance, and insurance requirements, with a two-year initial term plus one-year renewal option and potential FEMA funding. The Texas RFI requests vendor experience with direct contracting for self-insured employers and negotiated net pricing models outside traditional pharmacy benefit managers and group purchasing organizations.